Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Adenosine Diphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 10/20 | 0.87 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.87 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.87 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | SRC | P12931 | 2/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.87 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.87 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.87 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.81 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.81 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.81 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.81 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.77 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.77 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.77 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.77 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.77 |
| ▸ | LDHA | P00338 | 1/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Diphosphate SCHEMBL31158049 | 0.98 | P2RY1 (0.87) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL30929365 | 0.98 | P2RY1 (0.87) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL5498270 | 0.98 | P2RY1 (0.87) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL29467395 | 0.97 | P2RY1 (0.89) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL1496208 | 0.97 | P2RY1 (0.89) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL28397752 | 0.95 | P2RY1 (0.84) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL3040412 | 0.95 | P2RY1 (0.78) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL19947525 | 0.94 | P2RY1 (0.83) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL29573857 | 0.94 | P2RY1 (0.83) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL574960 | 0.94 | P2RY1 (0.83) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6255291-B1 | MIXTURE OF ALANINE, ADENOSINE COMPOUND, RIBOSE COMPOUND, ASCORBIC ACID AND NICOTINIC ACID | PEREGRINE PHARMACEUTICALS, INC. | 2001-07-03 | — | — | US | claimed |
| US-20120156278-A1 | SYSTEMS AND METHODS FOR PREPARING AUTOLOGOUS FIBRIN GLUE | CASCADE MEDICAL ENTERPRISES, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-20090258056-A1 | SYSTEMS AND METHODS FOR PREPARING AUTOLOGOUS FIBRIN GLUE | CASCADE MEDICAL ENTERPRISES, LLC (US) | 2009-10-15 | — | — | US | disclosed |
| US-20080199513-A1 | SYSTEMS AND METHODS FOR PREPARING AUTOLOGOUS FIBRIN GLUE | CASCADE MEDICAL ENTERPRISES, LLC (US) | 2008-08-21 | — | — | US | disclosed |
| US-6255291-B1 | MIXTURE OF ALANINE, ADENOSINE COMPOUND, RIBOSE COMPOUND, ASCORBIC ACID AND NICOTINIC ACID | PEREGRINE PHARMACEUTICALS, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0967984-A1 | COMPOSITION AND METHOD FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS RESULTING IN CHRONIC CONDITIONS | Peregrine Pharmaceutical, Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998046206-A1 | SKIN CREAM COMPOSITION | PEREGRINE PHARMACEUTICAL, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998039013-A1 | COMPOSITION AND METHOD FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS RESULTING IN CHRONIC CONDITIONS | PEREGRINE PHARMACEUTICAL, INC. (US) | 1998-09-11 | — | — | WO | disclosed |